MeiraGTx Holdings plc Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
MeiraGTx Holdings plc (MGTX) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $77.16 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-13
- MeiraGTx Holdings plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $5.44M.
- MeiraGTx Holdings plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$36.83M.
- MeiraGTx Holdings plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$10.67M.
- MeiraGTx Holdings plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$47.23M.
- MeiraGTx Holdings plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$38.19M.
- MeiraGTx Holdings plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$26.48M, a 308.65% decline from fiscal 2023.
- MeiraGTx Holdings plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $12.69M.
- MeiraGTx Holdings plc cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$22.86M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $77.16M 10-Q · filed 2026-08-13 | |||||||
| 2026-03-31 | $5.44M 10-Q · filed 2026-05-14 | |||||||
| 2025-12-31 | -$38.19M 10-K · filed 2026-03-30 | |||||||
| 2025-09-30 | -$89.06M 10-Q · filed 2025-11-13 | |||||||
| 2025-06-30 | -$76.08M 10-Q · filed 2026-08-13 | |||||||
| 2025-03-31 | -$36.83M 10-Q · filed 2026-05-14 | |||||||
| 2024-12-31 | -$26.48M 10-K · filed 2026-03-30 | |||||||
| 2024-09-30 | -$6.23M 10-Q · filed 2025-11-13 | |||||||
| 2024-06-30 | -$29.85M 10-Q · filed 2025-08-14 | |||||||
| 2024-03-31 | -$10.67M 10-Q · filed 2025-05-13 | |||||||
| 2023-12-31 | $12.69M 10-K · filed 2025-03-13 | |||||||
| 2023-09-30 | -$51.65M 10-Q · filed 2024-11-13 | |||||||
| 2023-06-30 | -$23.27M 10-Q · filed 2024-08-12 | |||||||
| 2023-03-31 | -$47.23M 10-Q · filed 2024-05-09 | |||||||
| 2022-12-31 | -$22.86M 10-K · filed 2024-03-15 | |||||||
| 2022-09-30 | -$22.93M 10-Q · filed 2023-11-14 | |||||||
| 2022-06-30 | -$65.15M 10-Q · filed 2023-08-10 | |||||||
| 2022-03-31 | -$23.34M 10-Q · filed 2023-05-11 | |||||||
| 2021-12-31 | -$70.54M 10-K · filed 2023-03-14 | |||||||
| 2021-09-30 | -$65.29M 10-Q · filed 2022-11-10 | |||||||
| 2021-06-30 | -$36.26M 10-Q · filed 2022-08-11 | |||||||
| 2021-03-31 | -$9.65M 10-Q · filed 2022-05-12 | |||||||
| 2020-12-31 | -$18.26M 10-K · filed 2022-03-10 | -$18.26M 10-K · filed 2021-03-11 | ||||||
| 2020-09-30 | -$47.90M 10-Q · filed 2021-11-10 | -$47.90M 10-Q · filed 2020-11-05 | ||||||
| 2020-06-30 | -$32.06M 10-Q · filed 2021-08-11 | -$32.06M 10-Q · filed 2020-08-06 | ||||||
| 2020-03-31 | -$16.25M 10-Q · filed 2021-05-11 | -$16.25M 10-Q · filed 2020-05-07 | ||||||
| 2019-12-31 | $158.91M 10-K · filed 2021-03-11 | |||||||
| 2019-09-30 | $185.55M 10-Q · filed 2020-11-05 | |||||||
| 2019-06-30 | $135.78M 10-Q · filed 2020-08-06 | |||||||
| 2019-03-31 | $158.62M 10-Q · filed 2020-05-07 | |||||||
| 2018-12-31 | $59.89M 10-K · filed 2020-03-11 | |||||||
| 2018-09-30 | $80.26M 10-Q · filed 2019-11-07 | |||||||
| 2018-06-30 | $93.73M 10-Q · filed 2019-08-07 | |||||||
| 2018-03-31 | $23.80M 10-Q · filed 2019-05-14 | |||||||
| 2017-12-31 | -$9.25M 10-K · filed 2019-03-26 | |||||||
| 2017-09-30 | -$12.52M 10-Q · filed 2018-11-08 | |||||||
| 2017-06-30 | -$12.66M 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |